AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Viking Therapeutics Inc. (VKTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

31.50

-0.79 (-2.45%)

At close: Feb 20, 2025, 3:59 PM

31.94

1.39%

After-hours: Feb 20, 2025, 06:55 PM EST

undefined% (undefined)

Bid	31.81
Market Cap	3.51B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.01
PE Ratio (ttm)	-31.19
Forward PE	n/a
Analyst	Buy

Ask	31.94
Volume	4,142,017
Avg. Volume (20D)	3,810,691
Open	32.20
Previous Close	32.29
Day's Range	31.14 - 33.22
52-Week Range	28.64 - 99.41
Beta	undefined

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also deve...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 28, 2015

Employees 30

Stock Exchange NASDAQ

Ticker Symbol VKTX

Website https://www.vikingtherapeutics.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for VKTX stock is "Buy." The 12-month stock price forecast is $102, which is an increase of 223.81% from the latest price.

Buy 92.86%

Hold 7.14%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 day ago New

+10.36%

Viking Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

1 week ago

-7.34%

Viking Therapeutics shares are trading lower after B. Riley Securities and Maxim Group cut their respective price targets on the stock.

News

1 week ago · schaeffersresearch.com

3 Weight-Loss Drug Stocks to Watch

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO) , and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most...

1 week ago · fool.com

2 Stocks to Buy With Less Than $40

Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look excit...

1 week ago · fool.com

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.

1 week ago · fool.com

2 Stocks That Could Soar Again in 2025

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (VKTX 3.50%) and Summit Therapeutics (SMMT -2.71%).

1 week ago · fool.com

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

Nearly a year ago, Viking Therapeutics (VKTX 3.50%) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug.

2 weeks ago · zacks.com

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

2 weeks ago · fool.com

Has the Bubble Burst for Viking Therapeutics Stock?

The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value.

2 weeks ago · investors.com

Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Re...

2 weeks ago · seekingalpha.com

Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO C...

2 weeks ago · zacks.com

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Load More News